Effects of Glutamine on GLP-1 and Insulin Secretion in Man

Garvan Institute of Medical Research

Status: Completed

Conditions: Type 2 Diabetes

Treatments: Drug: Sitagliptin; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT00673894

H07/059

Details and patient eligibility

About

This study investigated the effect of glutamine, an amino acid, glycemia, glucagon-like peptide-1 (GLP-1) and insulin in participants with type 2 diabetes.

Full description

In this study, we investigated the effect of glutamine, an amino acid, on glycemia and on GLP-1 and insulin in participants with type 2 diabetes. Preliminary data published by our group suggests that glutamine is a strong determinant of GLP-1 secretion in vitro. We tested the hypothesis that glutamine lowers postprandial blood glucose and investigated whether the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin modifies this effect.

Enrollment: 22 patients

Sex: All

Ages: 40 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetes, on metformin or diet alone (not sulphonylureas or insulin)

Exclusion criteria

• Malabsorption, renal or liver disease, treatment with steroids

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

22 participants in 2 patient groups, including a placebo group

Glutamine+Sitagliptin

Experimental group

Description:

Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin

Treatment:

Drug: Sitagliptin

Glutamine+Placebo

Placebo Comparator group

Description:

Glutamine 30 g/d (15 g with breakfast and dinner) + placebo

Treatment:

Drug: Placebo